List view / Grid view
New data presented at the European Society of Cardiology (ESC) Congress 2023, showed Novartis’ Leqvio® (inclisiran) provided an approximate 49 percent reduction in LDL cholesterol beyond six years of clinical observation.
In this podcast, Paul Nioi, Vice President of Discovery and Translational Research at Alnylam Pharmaceuticals discusses the clinical development and manufacturing of RNA interference (RNAi) therapeutics.
An RNAi therapeutic that has best-in-disease potential for hypertension is set to be developed under a partnership between Roche and Alnylam Pharmaceuticals.
The developers of givosiran announced the European Commission (EC) has granted the drug marketing authorisation based on results of the Phase III ENVISION trial.
Lumasiran, an investigational drug to treat primary hyperoxaluria type 1, has met its endpoints in clinical trials.
1 October 2015 | By Victoria White
Genzyme has elected to opt into the programme for development and potential future commercialisation of ALN-AT3 in territories outside of North America and Western Europe...
21 May 2015 | By Victoria White
The FDA has granted Orphan Drug Designation to Alnylam’s revusiran for the treatment of transthyretin (TTR)-mediated amyloidosis (ATTR amyloidosis)...
